What is GeneCapture?
GeneCapture has developed the CAPTURE Platform, a portable technology solution for rapid pathogen identification and antibiotic susceptibility testing. This innovative platform allows for pathogen identification in one hour and antibiotic susceptibility testing in two hours, using various sample types without the need for refrigeration or lab equipment. The company aims to provide fast, accurate, and actionable answers in diverse environments, including clinics, communities, farms, and battlefields. GeneCapture's mission is to enhance healthcare by reducing the time to identify infections and ensuring timely treatment, especially in the face of growing antimicrobial resistance.
How much funding has GeneCapture raised?
GeneCapture has raised a total of $85K across 2 funding rounds:
Debt
$35K
Debt
$50K
Debt (2021): $35K with participation from PPP
Debt (2026): $50K, investors not publicly disclosed
Key Investors in GeneCapture
PPP
Public-Private Partnership
What's next for GeneCapture?
With the recent influx of capital, GeneCapture is poised for significant growth and market penetration. The expansion capital will likely fuel further research and development, scale manufacturing capabilities, and broaden the commercialization efforts for the CAPTURE Platform. This strategic investment positions GeneCapture to address critical needs in infectious disease diagnostics across various sectors, potentially revolutionizing how pathogens are identified and treated globally.
See full GeneCapture company page
